Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;99(12):2184-7.
doi: 10.2105/AJPH.2009.159889. Epub 2009 Oct 15.

Changes in postmenopausal hormone replacement therapy use among women with high cardiovascular risk

Angela Hsu  1 , Andrea Card, Susan Xiaoqin Lin, Sean Mota, Olveen Carrasquillo, Andrew Moran
Affiliations

Changes in postmenopausal hormone replacement therapy use among women with high cardiovascular risk

Angela Hsu et al. Am J Public Health. 2009 Dec.

Abstract

After randomized trials failed to support the use of hormone replacement therapy (HRT) for preventing cardiovascular disease (CVD), HRT use for postmenopausal women declined. Our analysis of 1999-2000 and 2003-2004 National Health and Nutrition Surveys (NHANES) shows that HRT use decreased 19% (from 27.6 to 8.4%; P<.001) among women with CVD versus 3% (from 19.8 to 16.8%; P=.68) among low-risk women, suggesting that most of the drop in HRT use may be among women prescribed HRT as an unproven treatment to prevent CVD.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Change in hormone replacement therapy (HRT) use by number of cardiovascular disease (CVD) risk factors: US National Health and Nutrition Examination Surveys (NHANES), 1999–2000 and 2003–2004. Note. P is for absolute change in proportion between surveys, determined by use of a t statistic.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291(1):47–53 - PubMed
    1. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004;292(16):1983–1988 - PubMed
    1. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291(14):1701–1712 - PubMed
    1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group [see comment]. JAMA 1998;280(7):605–613 - PubMed
    1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial [see comment]. JAMA 2002;288(3):321–333 - PubMed

LinkOut - more resources